13 Most Undervalued Long-Term Stocks to Buy According to Analysts

​9. Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal entails access to Novo’s GLP-1 drugs, Ozempic and Wegovy, at Hims & Hers’ platform.

​Management noted that as part of this deal, Hims & Hers will sell FDA-approved Ozempic injections and Wegovy in tablet form and injections at “affordable self-pay prices” matching other telehealth sites. Moreover, Hims and Hers will also stop selling and advertising compounded GLP-1s; as a result, existing patients will have the opportunity to use FDA-approved treatments.

​In addition, Novo Nordisk is also dropping its patent lawsuit against Hims & Hers, but can refile later. NVO’s CEO Mike Doustdar noted this as a “win for patients” by prioritizing safe, proven FDA-approved meds over riskier compounds. It counters competition from telehealth firms undercutting prices with unapproved knockoffs, which have surged amid GLP-1 demand.

​Novo Nordisk A/S (NYSE:NVO) is a global healthcare company that develops, manufactures, and markets medicines for serious chronic diseases. It is a leader in diabetes care (including insulin and Ozempic), obesity management (Wegovy), haemophilia care, and rare endocrine disorders.